Literature DB >> 24073013

Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.

Raymond C Givens1, Chris Russo, Philip Green, Mathew S Maurer.   

Abstract

AIMS: In the USA, transthyretin cardiac amyloidosis usually results from 'wild-type' transthyretin (senile cardiac amyloidosis [SCA]) or the V122I variant. PATIENTS &
METHODS: We compared presentations and outcomes among SCA and V122I patients referred to the Center for Advanced Cardiac Care at Columbia University Medical Center (NY, USA) between 2001 and 2012.
RESULTS: V122I patients were younger (mean: 71 years, standard deviation [SD]: 7) than SCA patients (mean: 77, SD: 6; p = 0.0002) and 96% were black compared with 3% of SCA patients (p < 0.0001). Average ejection fraction was lower among V122I patients (mean: 25% [SD: 12] vs mean: 47% [SD: 15]; p = 0.0001), as was mean cardiac index. Median time to death or orthotopic heart transplant was 36.4 months for V122I patients and 66.5 for SCA patients (p = 0.09).
CONCLUSION: In this study of patients with transthyretin cardiac amyloidosis, V122I patients presented to a tertiary academic medical center at a younger age than SCA patients but had higher levels of cardiac dysfunction, despite genetic screening availability. There was a trend toward shorter time to orthotopic heart transplant or death among V122I patients. Whether this is a result of a different biologic progression or late diagnosis requires further study.

Entities:  

Keywords:  African–American; amyloidosis; elderly; heart failure; transthyretin

Year:  2013        PMID: 24073013      PMCID: PMC3780445          DOI: 10.2217/ahe.13.10

Source DB:  PubMed          Journal:  Aging health        ISSN: 1745-509X


  16 in total

Review 1.  Tafamidis for transthyretin amyloidosis.

Authors:  J de Lartigue
Journal:  Drugs Today (Barc)       Date:  2012-05       Impact factor: 2.245

2.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 3.  Ethnic distribution of amyloidosis: an autopsy study.

Authors:  F S Buck; M N Koss; A E Sherrod; A Wu; M Takahashi
Journal:  Mod Pathol       Date:  1989-07       Impact factor: 7.842

4.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

Authors:  Frederick L Ruberg; Mathew S Maurer; Daniel P Judge; Steven Zeldenrust; Martha Skinner; Antony Y Kim; Rodney H Falk; Kin N Cheung; Ayan R Patel; Arian Pano; Jeffrey Packman; Donna Roy Grogan
Journal:  Am Heart J       Date:  2012-08       Impact factor: 4.749

6.  Revised transthyretin Ile 122 allele frequency in African-Americans.

Authors:  D R Jacobson; R Pastore; S Pool; S Malendowicz; I Kane; A Shivji; S H Embury; S K Ballas; J N Buxbaum
Journal:  Hum Genet       Date:  1996-08       Impact factor: 4.132

7.  Transthyretin cardiac amyloidoses in older North Americans.

Authors:  Kumar Dharmarajan; Mathew S Maurer
Journal:  J Am Geriatr Soc       Date:  2012-02-13       Impact factor: 5.562

8.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.

Authors:  Z Lai; W Colón; J W Kelly
Journal:  Biochemistry       Date:  1996-05-21       Impact factor: 3.162

Review 9.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

10.  The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.

Authors:  Jason Dungu; Prayman T Sattianayagam; Carol J Whelan; Simon D J Gibbs; Jennifer H Pinney; Sanjay M Banypersad; Dorota Rowczenio; Janet A Gilbertson; Helen J Lachmann; Ashutosh Wechalekar; Julian D Gillmore; Philip N Hawkins; Lisa J Anderson
Journal:  Am Heart J       Date:  2012-07       Impact factor: 4.749

View more
  28 in total

1.  Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

Authors:  Pooja Phull; Vaishali Sanchorawala; Lawreen H Connors; Gheorghe Doros; Frederick L Ruberg; John L Berk; Shayna Sarosiek
Journal:  Amyloid       Date:  2018-02-09       Impact factor: 7.141

Review 2.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

3.  Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis.

Authors:  Sabahat Bokhari; Rachelle Morgenstern; Richard Weinberg; Mona Kinkhabwala; Demetrios Panagiotou; Adam Castano; Albert DeLuca; Andrew Kontak; Zhezhen Jin; Mathew S Maurer
Journal:  J Nucl Cardiol       Date:  2016-08-31       Impact factor: 5.952

Review 4.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 5.  Transthyretin Cardiac Amyloidosis in Older Americans.

Authors:  Danielle L Brunjes; Adam Castano; Autumn Clemons; Jonah Rubin; Mathew S Maurer
Journal:  J Card Fail       Date:  2016-10-18       Impact factor: 5.712

Review 6.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Perry Elliott; Raymond Comenzo; Marc Semigran; Claudio Rapezzi
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

7.  Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?

Authors:  Fabian Aus dem Siepen; Selina Hein; Sofie Prestel; Christian Baumgärtner; Stefan Schönland; Ute Hegenbart; Christoph Röcken; Hugo A Katus; Arnt V Kristen
Journal:  Clin Res Cardiol       Date:  2019-04-05       Impact factor: 5.460

8.  TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.

Authors:  Hannah Rosenblum; Adam Castano; Julissa Alvarez; Jeff Goldsmith; Stephen Helmke; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2018-04       Impact factor: 8.790

9.  Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal.

Authors:  Adam Castaño; Daniel K Manson; Mathew S Maurer; Sabahat Bokhari
Journal:  Curr Cardiovasc Risk Rep       Date:  2017-04-25

10.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).

Authors:  Mathew S Maurer; Mazen Hanna; Martha Grogan; Angela Dispenzieri; Ronald Witteles; Brian Drachman; Daniel P Judge; Daniel J Lenihan; Stephen S Gottlieb; Sanjiv J Shah; D Eric Steidley; Hector Ventura; Srinivas Murali; Marc A Silver; Daniel Jacoby; Savitri Fedson; Scott L Hummel; Arnt V Kristen; Thibaud Damy; Violaine Planté-Bordeneuve; Teresa Coelho; Rajiv Mundayat; Ole B Suhr; Márcia Waddington Cruz; Claudio Rapezzi
Journal:  J Am Coll Cardiol       Date:  2016-07-12       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.